drugset / Trial / NCT00889330

Safety and Efficacy Study of a Eye Drop for Eye Allergy

NCT00889330

Phase 3 Completed 60 enrolled Vistakon Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.

Timeline

Start
2009-04
Primary completion
2009-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Alcaftadine Small molecule 0.25 % Other

Indications